Abstract
Immunotoxicity is defined as the toxicological effects of xenobiotics including pharmaceuticals on the functioning of the immune system and can be induced in either direct or indirect ways. Direct immunotoxicity is caused by the effects of chemicals on the immune system, leading to immunosuppression and subsequently to reduced resistance to infectious diseases or certain forms of nongenotoxic carcinogenicity.
In vitro testing has several advantages over in vivo testing, such as detailed mechanistic understanding, species extrapolation (parallelogram approach), and reduction, refinement, and replacement of animal experiments. In vitro testing for direct immunotoxicity can be done in a two-tiered approach, the first tier measuring myelotoxicity. If this type of toxicity is apparent, the compound can be designated immunotoxic. If not, the compound is tested for lymphotoxicity (second tier). Several in vitro assays for lymphotoxicity exist, each comprising specific functions of the immune system (cytokine production, cell proliferation, cytotoxic T-cell activity, natural killer cell activity, antibody production, and dendritic cell maturation). A brief description of each assay is provided. Only one assay, the human whole blood cytokine release assay, has undergone formal prevalidation, while another one, the lymphocyte proliferation assay, is progressing towards that phase.
Progress in in vitro testing for direct immunotoxicity includes prevalidation of existing assays and selection of the assay (or combination of assays) that performs best. To avoid inter-species extrapolation, assays should preferably use human cells. Furthermore, the use of whole blood has the advantage of comprising multiple cell types in their natural proportion and environment. The so-called “omics” techniques provide additional mechanistic understanding and hold promise for the characterization of classes of compounds and prediction of specific toxic effects. Technical innovations such as high-content screening and high-throughput analysis will greatly expand the opportunities for in vitro testing.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Snodin DJ (2004) Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development? Regul Toxicol Pharmacol 40:336–355
Balls M, Goldberg AM, Fentem JH et al (1995) The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. Altern Lab Anim 23:838–866
Gennari A, Ban M, Braun A et al (2005) The use of in vitro systems for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop. J Immunotoxicol 2:61–83
Carfi’ M, Gennari A, Malerba I et al (2007) In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicology 229:11–22
International Programme on Chemical Safety (IPCS) (1996) Principles and methods for assessing direct immunotoxicity associated with exposure to chemicals. Environmental health criteria 180. World Health Organization, Geneva
Pessina A, Albella B, Bueren J et al (2001) Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 15:729–740
Pessina A, Albella B, Bayo M et al (2003) Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355–367
Vandebriel RJ, Garssen J, Van Loveren H (1995) Methods in immunotoxicology. In: Phillips MI, Evans D (eds) Neuroimmunology. Methods in Neuroscience, vol 24. Academic, San Diego, pp 151–169
Langezaal I, Hoffmann S, Hartung T, Coecke S (2002) Evaluation and prevalidation of an immunotoxicity test based on human whole-blood cytokine release. Altern Lab Anim 30:581–595
Hartung T, Wendel A (1996) Detection of pyrogens using human whole blood. In Vitro Toxicol 9:353–359
Smialowicz RJ (1995) Immune function testing for the identification and characterisation of immunotoxicity in rodents. Hum Exp Toxicol 14:135–136
House RV, Thomas PT (1995) In vitro induction of cytotoxic T lymphocytes. In: Burleson GR, Dean JH, Munson AE (eds) Methods in immunotoxicology, Wiley-Liss, NY, pp 159–171
Cederbrant K, Marcusson-Ståhl M, Condevaux F, Descotes J (2003) NK-cell activity in immunotoxicity drug evaluation. Toxicology 185:241–250
Kane KL, Ashton FA, Schmitz JL, Folds JD (1996) Determination of natural killer cell function by flow cytometry. Clin Diagn Lab Immunol 3:295–300
Marcusson-Ståhl M, Cederbrant K (2003) A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxicology 193:269–279
Stewart CC, Cookfair DL, Hovey KM et al (2003) Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom 53:26–33
Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187–376
Koeper LM, Vohr HW (2009) Functional assays are mandatory for a correct prediction of immunotoxic properties of compounds in vitro. Food Chem Toxicol 47(1):110–118
Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255–258
Toebak MJ, de Rooij J, Moed H et al (2008) Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs. Br J Dermatol 158:225–233
Ullerås E, Trzaska D, Arkusz J et al (2005) Development of the “Cell Chip”: a new in vitro alternative technique for immunotoxicity testing. Toxicology 206:245–256
Ringerike T, Ullerås E, Völker R et al (2005) Detection of immunotoxicity using T-cell based cytokine reporter cell lines (“Cell Chip”). Toxicology 206:257–272
Trzaska D, Zembek P, Olszewski M et al (2005) “Fluorescent Cell Chip” for immunotoxicity testing: development of the c-fos expression reporter cell lines. Toxicol Appl Pharmacol 207(2 Suppl):133–141
Wagner W, Walczak-Drzewiecka A, Slusarczyk A et al (2006) Fluorescent Cell Chip a new in vitro approach for immunotoxicity screening. Toxicol Lett 162:55–70
de Longueville F, Bertholet V, Remacle J (2004) DNA microarrays as a tool in toxicogenomics. Comb Chem High Throughput Screen 7:207–211
Tugwood JD, Hollins LE, Cockerill MJ (2003) Genomics and the search for novel biomarkers in toxicology. Biomarkers 8:79–92
Steiner G, Suter L, Boess F et al (2004) Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect 112:1236–1248
Waters, M.D. and Fostel, J.M (2004) Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet 5:936–948
Burczynski ME, McMillian M, Ciervo J et al (2000) Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 58:399–415
Thomas RS, Rank DR, Penn SG et al (2001) Identification of toxicologically predictive gene sets using cDNA microarrays. Mol Pharmacol 60:1189–1194
Waring JF, Jolly RA, Ciurlionis R et al (2001) Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 175:28–42
Hamadeh HK, Bushel PR, Jayadev S, et al (2002) Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219–231
Baken KA, Pennings JL, Jonker MJ et al (2008) Overlapping gene expression profiles of model compounds provide opportunities for immunotoxicity screening. Toxicol Appl Pharmacol 226:46–59
Patterson RM, Germolec DR (2006) Gene expression alterations in immune system pathways following exposure to immunosuppressive chemicals. Ann N Y Acad Sci 1076:718–727
Baken KA, van Loveren H, Pennings JL et al (2006) Gene expression profiling of Bis(tri-n-butyltin)oxide (TBTO)-induced immunotoxicity in Mice and Rats. J Immunotoxicol 3:227–244
Baken KA, Vandebriel RJ, Pennings JL et al (2007) Toxicogenomics in the assessment of immunotoxicity. Methods 41:132–141
Burns-Naas LA, Dearman RJ, Germolec DR et al (2006) Omics technologies and the immune system. Tox Mech Methods 16:101–119
Baken KA, Arkusz J, Pennings JL et al (2007) In vitro immunotoxicity of bis(tri-n-butyltin)oxide (TBTO) studied by toxicogenomics. Toxicology 237:35–48
Ezendam J, Staedtler F, Pennings J et al (2004) Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. Environ Health Perspect 112:782–791
Luebke RW, Holsapple MP, Ladics GS et al (2006) Immunotoxicogenomics: the potential of genomics technology in the immunotoxicity risk assessment process. Toxicol Sci 94:22–27
Van Loveren H, De Jong WH, Vandebriel RJ et al (1998) Risk assessment and immunotoxicology. Toxicol Lett 102–103:261–265
Van Loveren H, Slob W, Vandebriel RJ et al (1998) Immunotoxicology: extrapolation from animal to man–estimation of the immunotoxicologic risk associated with TBTO exposure. Arch Toxicol Suppl 20:285–292
Brandon EF, Raap CD, Meijerman I et al (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–246
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lankveld, D.P.K., Van Loveren, H., Baken, K.A., Vandebriel, R.J. (2010). In Vitro Testing for Direct Immunotoxicity: State of the Art. In: Dietert, R. (eds) Immunotoxicity Testing. Methods in Molecular Biology™, vol 598. Humana Press. https://doi.org/10.1007/978-1-60761-401-2_26
Download citation
DOI: https://doi.org/10.1007/978-1-60761-401-2_26
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-400-5
Online ISBN: 978-1-60761-401-2
eBook Packages: Springer Protocols